RxDoctor Payments Data

Allison Landreth, APRN

Family · Maysville, KYNPI 1134788227

Payments from drug & device makers

$1,882in general payments, 2019–2025

Across 140 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$782
  • Amgen$185
  • Novo Nordisk$118
  • Corcept Therapeutics$104
  • Mannkind Corporation$102
  • GSK$96
  • plus $493 from 15 others

What the payments were for

  • Food & beverage$1,882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,882 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,256
Medicare patients
33
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$64,376
MounjaroTirzepatide41$42,457
JardianceEmpagliflozin42$38,315
FarxigaDapagliflozin Propanediol38$28,402
JanuviaSitagliptin Phosphate29$28,020
RexultiBrexpiprazole15$24,772
EliquisApixaban19$24,310
XareltoRivaroxaban13$20,456
MyrbetriqMirabegron18$18,463
AuvelityDextromethorphan Hbr/Bupropion12$15,776
LinzessLinaclotide21$15,578
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,975
Repatha SureclickEvolocumab12$7,721
GemtesaVibegron12$6,204
SymbicortBudesonide/Formoterol Fumarate27$5,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$118$64,37667 claims
Lilly USA, LLCMounjaro$61$42,45741 claims
AstraZenecaFarxiga, Symbicort$26$34,09465 claims
Otsuka America Pharmaceutical, Inc.Rexulti$30$24,77215 claims
PfizerEliquis$31$24,31019 claims
Axsome Therapeutics, Inc.Auvelity$59$15,77612 claims
AbbVieLinzess$782$15,57821 claims
GSKTrelegy Ellipta$96$11,97515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Maysville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →